# OnCo record richard-finn (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/richard-finn/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "richard-finn" ;
  schema:name "Richard S. Finn"@en ;
  schema:description "Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer."@en ;
  schema:url <https://onco.cc/people/richard-finn/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab> ;
  onco:tag "breast", "hcc", "trialist" ;
  schema:jobTitle "Professor of Medicine, UCLA Jonsson Comprehensive Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:institutions <https://onco.cc/institutions/ucla-jonsson/> ;
  onco:trials <https://onco.cc/trials/paloma-2/>, <https://onco.cc/trials/imbrave150/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-imbrave150-nejm-2020/> ;
  schema:affiliation <https://onco.cc/institutions/ucla-jonsson/> .